A Trial to Learn if Linvoseltamab is Safe and Works in Adults with Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)

Prior treatment

• Myocardial infarction within the past 6 months prior to the first screening visit
• Known active infection requiring hospitalization or treatment with IV anti-infectives within 28 days of first administration of study drug

Other illness

• History of other non-AL amyloidosis

Other

• Greater than 60% plasmacytosis on a bone marrow biopsy and/or aspirate during screening
• Presence of lytic bone lesion(s) or extramedullary plasmacytoma on imaging during screening
• NOTE: Other protocol defined exclusion criteria apply

• Confirmed diagnosis of AL amyloidosis, as described in the protocol
• Measurable disease as defined by serum difference between involved and uninvolved free light chains (dFLC) concentration, as described in the protocol
• Previously treated after at least 1 prior therapy and requiring further treatment as assessed by the Investigator
• N-terminal pro b-type natriuretic peptide (NT-proBNP) ≤8500 ng/L during screening
• Adequate hepatic, hematologic, renal, and cardiac function, as described in the protocol
• Eastern Cooperative Oncology Group (ECOG) performance score ≤2 at screening
• NOTE: Other protocol defined inclusion criteria apply